Results 231 to 240 of about 12,447,623 (292)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Work Functions at Facet Edges

Physical Review Letters, 2002
We perform ab initio pseudopotential calculations for metal crystals with finite facets of different crystallographic orientation to investigate the work function profile near crystal edges. We examine local edge effects, and address the problem of the coexistence of different face-dependent local work functions at crystal edges.
FALL CJ   +2 more
openaire   +3 more sources

Measuring Work Functioning: Validity of a Weighted Composite Work Functioning Approach

Journal of Occupational Rehabilitation, 2015
To examine the construct validity of a weighted composite work functioning measurement approach.Workers (health-impaired/healthy) (n = 117) completed a composite measure survey that recorded four central work functioning aspects with existing scales: capacity to work, quality of work performance, quantity of work, and recovery from work.
Boezeman, Edwin J.   +2 more
openaire   +2 more sources

Scanning work function microscopy

Analytical and Bioanalytical Chemistry, 1996
When a sample is locally excited with a highly focused raster-scanned beam of keV electrons, the variations DeltaPhi of the work function across the surface can be monitored from the shift of the onset energy for secondary electron emission along a fixed energy scale.
openaire   +2 more sources

Work Function and Temperature

Physical Review, 1941
The change in height of the potential energy barrier at the surface of a metal with the expansion of the metal due to heating is investigated. Also, the change of the normal maximum energy of an electron in a metal is calculated as a function of the temperature of the metal. These calculations show that the work function of a metal is a linear function
openaire   +2 more sources

Home - About - Disclaimer - Privacy